Table 1.
Adverse events experienced by patients treated with antiviral schedule regimens
| SOF/LDV | SOF/DAK | SOF/SIM+/− RBV | SOF/RBV | OMB/PTR/r/DAS +/− RBV | |
|---|---|---|---|---|---|
| ENROLLED PTS per regimen | 20 | 15 | 28 | 4 | 11 |
| PTS WITH SERIOUS ADRs | 4 (20%) | 3 (20%) | 1 (4%) | 1 (25%) | 1 (9%) |
| DISCONTINUATION | 3 | 0 | 0 | 0 | 1 |
| DEATHS | 0 | 0 | 0 | 0 | 0 |
| COMMON ADRs | 10 (50%) | 6 (40%) | 12 (43%) | 4 (100%) | 5 (45%) |
| FATIGUE | 6 | 5 | 11 | 4 | 4 |
| HEADACHE | 0 | 0 | 0 | 0 | 0 |
| NAUSEA | 0 | 0 | 0 | 0 | 0 |
| PRURITUS | 0 | 0 | 4 | 0 | 0 |
| INSOMNIA | 1 | 3 | 0 | 0 | 0 |
| DIARRHOEA | 0 | 0 | 0 | 0 | 0 |
| ASTHENIA | 7 | 2 | 11 | 4 | 3 |
| RASH | 0 | 0 | 4 | 0 | 0 |
| IRRITABILITY | 0 | 4 | 0 | 0 | 0 |
| ANAEMIA | 6 | 3 | 12 | 3 | 3 |
| DYSPNOEA | 2 | 0 | 0 | 0 | 1 |
*Common adverse drug reactions are not to single patients, one patient may experience more than one common adverse drug reaction. Data are expressed as absolute number plus percentage